Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Choline attenuates lipopolysaccharide-induced neuroinflammation in the BV-2 microglial cell line via the α7 nicotinic acetylcholine receptor/nuclear factor kappa-B signaling pathway.

Created on 10 Nov 2026

Authors

ZhengLong Xia, DuoGan Wang, XiaoQi Qiu, ShaoWen Huang, YanXiong Wen, YiShuang Huang

Published in

Neuroscience letters. Pages 138782. Nov 09, 2026. Epub Nov 09, 2026.

Abstract

This study aimed to investigate the potential mechanisms by which choline (CHO) attenuates lipopolysaccharide (LPS)-induced neuroinflammatory responses in BV-2 microglial cells through network pharmacology-based prediction and in vitro experiments. These neuroinflammatory responses are implicated in the pathophysiology of sepsis-associated encephalopathy (SAE).
Putative CHO targets were retrieved from PubChem, the Comparative Toxicogenomics Database (CTD), and SwissTargetPrediction, while SAE-associated genes were sourced from OMIM and GeneCards. Overlapping targets from both datasets were subjected to protein-protein interaction (PPI) network construction, along with Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, to identify core candidate genes and key signaling cascades. The predicted outcomes were subsequently verified by in vitro experiments, including cell viability assays, enzyme-linked immunosorbent assay (ELISA), immunofluorescence, quantitative polymerase chain reaction (qPCR), and Western blot.
An intersection of 672 SAE-associated genes and 109 CHO-responsive genes yielded 24 common targets. Among them, TNF, IL10, IL6, MMP9, and IL1B were identified as potential hub therapeutic targets. KEGG enrichment analysis revealed the involvement of multiple pathways, with the nuclear factor kappa-B (NF-κB) cascade being particularly notable. In cell-based assays, CHO administration reduced the levels of pro-inflammatory mediators (TNF-α, IL-1β, and IL-6) and concurrently increased those of anti-inflammatory markers (IL-4, IL-10, and CD206). Furthermore, CHO elevated α7 nicotinic acetylcholine receptor (α7nAChR) expression while suppressing IκBα and NF-κB p65 phosphorylation. Treatment with the α7nAChR antagonist methyllycaconitine citrate (MLA) reversed these effects.
CHO may inhibit microglial neuroinflammation and promote anti-inflammatory polarization, potentially via the α7nAChR/NF-κB signaling pathway.

PMID:
43003219
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement